Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > PP speculation

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Jul 04, 2024 12:15pm

247 Views

Post# 36118275

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:PP speculation

Thanks for the post DJDawg. It all sounds right to me.

They have demonstrated that Rutherrin works much better than TLD1433 by itself as an anti-cancer PS. When I wrote them years ago to ask why they were using TLD1433 (Ruvidar) rather than Rutherrin in the NMIBC trial they told me that Rutherrin just wasn't ready yet. Theralase was in no position to wait another year or two before starting the phase 1 trial.

This from Pavel Kaspler and colleagues 2016 pqper:

We present data showing that premixing the Ru2+-complex TLD1433 with transferrin increases the molar extinction coefficient, including longer activation wavelengths, reduces photobleaching rates, reduces the toxicity of the complex and improving overall PDT efficacy. As the transferrin receptor is upregulated in most malignancies, premixing of the Ru2+ complex with transferrin converts the active pharmaceutical ingredient TLD1433 into a drug of potentially considerable clinical utility.

Ruthenium(II) based Photosensitizer and Transferrin Complexes Enhance Photo-physical Properties, Cell Uptake, and Photodynamic Therapy Safety and Efficacy

This all begs the question - once the current NMIBC trial is complete and Theralase is adequately funded at last, wouldn't it make sense to conduct a new NMIBC trial using Rutherrin rather than Ruvidar? Maybe they would get even better results.

DJDawg wrote:
A few add on comments (please correct me if anything I say is incorrect)

Ruvidar is the brand name for tld-1433, for the bladder

My understanding is that Rutherrin is the brand name for tld-1433 combined with transferrin.
Transferrin is a protein that floats around in blood and binds iron. It then presents itself to the outside of a cell. If the cell needs iron it expresses way more of something called transferrin receptor. Cancer cells have been show to have a lot of transferrin receptors as they are trying to grab any iron passing by. TLD-1433, contains ruthenium which is in the same column of the period table as iron. Same column means many similar properties. So transferrin protein seems to happily bind to tld-1433 and then when passing by, the cancer cell would grab it, assuming it is iron. Now it is in the cell. Trojan horsing it I guess.

I believe that the planned way to do this treatment is to premix the transferrin protein with the tld-1433 and then give it. That way already packaged and ready to go rather than depending on the tld-1433 wandering around looking for the patient's transferrin to bind to.

Eog can correct me but my understanding is Rutherrin is tld-1433 packaged together with transferrin to make the treatment drug.